BioMarin Pharmaceutical's (NASDAQ: BMRN) long-term positive thesis remains unchanged, said RBC Capital analyst Michael J. Yee. Comments follow the release ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Trader Talk

BioMarin (BMRN) PT Cut to $100 at Baird; Sees Drisapersen Approval 'Near-Zero'November 23, 2015 7:16 AM FDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - BairdNovember 23, 2015 6:55 AM BioMarin (BMRN) PT Trimmed at Wedbush Following Briefing Docs; Sees Positive Read-Thru to SRPT, None to PTCTNovember 20, 2015 12:33 PM Concerns on Drisapersen Positive for Sarepta's (SRPT) Eteplirsen - Needham & Company November 20, 2015 11:19 AM Despite Harsh BioMarin (BMRN) Briefing Docs, the Jury is Still Out - Leerink Partners November 20, 2015 10:21 AM BioMarin Pharma (BMRN) Briefing Docs 'Ugly' - Baird (SRPT)November 20, 2015 9:50 AM FDA Posts Breifing Docs for BioMarin Pharma's (BMRN) DrisapersenNovember 20, 2015 7:59 AM BioMarin Pharma (BMRN) FDA briefing docs releasedNovember 20, 2015 7:59 AM Baird Expects FDA Rejection for Drisapersen and Eteplirsen (BMRN) (SRPT)November 19, 2015 8:18 AM